Also known as: compounded semaglutide, oral Wegovy, Semaglyn, SEMAGLYN
Semaglutide is a GLP-1 analogue marketed as OZEMPIC for type 2 diabetes and cardiovascular risk reduction in adults with established cardiovascular disease. It acts as a GLP-1 receptor agonist with glucose-dependent stimulation of insulin secretion, suppression of glucagon secretion, and minor delay of gastric emptying. U.S. initial approval in this label is 2017.
HHS launches broad initiative to boost US clinical trials amid global competition with China. FDA introduces real-time clinical trial monitoring and expedited programs. NIH Long COVID trials set to begin enrolling participants in summer 2026.
AstraZeneca is advancing its oral GLP-1 drug into Phase III trials while defending dapagliflozin patents in Australia. The company obtained an Australian court injunction against a generic competitor and has partnered with Evinova to use AI for clinical trials. India could be a future market for the oral GLP-1 drug pending global trial data.
The Delhi High Court ruled Dr. Reddy's can export semaglutide, finding Novo Nordisk's patent unenforceable. Dr. Reddy's plans to launch generic Wegovy at 60% discount pending approval.
The FDA announced new enforcement priorities on February 6, 2026, to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded drugs being mass-marketed. The action follows an August 2025 citizens' petition arguing that large-scale compounded semaglutide production poses public health risks including lack of immunogenicity assessments and misleading marketing practices.
NICE updates type 2 diabetes guidance in England, recommending earlier use of SGLT-2 inhibitors and GLP-1 receptor agonists. Separately, a study finds SGLT2 inhibitors improve survival in Takotsubo syndrome patients.
Wegovy and Mounjaro prices in South Korea are higher than in China and Japan. South Korea added both drugs to a non-insurance reporting system, but immediate price cuts are unlikely.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
SoSoThin.com launched a cash-pay semaglutide weight loss service on February 16, 2026. The company said the model offers fast access, transparent pricing, and a digital-first process without insurance delays.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07617155 |
GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis |
NOT_YET_RECRUITING | PHASE4 |
| NCT07610174 |
Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves |
COMPLETED | PHASE2 |
| NCT07592546 |
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss |
NOT_YET_RECRUITING | PHASE4 |
| NCT07588984 |
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study |
NOT_YET_RECRUITING | |
| NCT07570810 |
Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM |
NOT_YET_RECRUITING | NA |
| NCT07564414 |
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight |
RECRUITING | PHASE3 |
| NCT07554417 |
Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1 |
NOT_YET_RECRUITING | PHASE4 |
| NCT07547878 |
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) |
NOT_YET_RECRUITING | PHASE4 |
| NCT07527195 |
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) |
RECRUITING | PHASE1 |
| NCT07523633 |
Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder |
RECRUITING | PHASE2 |
